OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

The perspective of immunotherapy

(2014) Christian U. Blank   CURRENT OPINION IN ONCOLOGY

FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs

(2013) Ann L. White et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

(2013) Aurélien Marabelle et al.   JOURNAL OF CLINICAL INVESTIGATION

Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies

(2013) Jeong M. Kim et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Pancreatic Islet Xenograft Survival in Mice Is Extended by a Combination of Alpha-1-Antitrypsin and Single-Dose Anti-CD4/CD8 Therapy

(2013) Efrat Ashkenazi et al.   PLoS One

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Modulation of GITR for cancer immunotherapy

(2012) David A Schaer et al.   CURRENT OPINION IN IMMUNOLOGY

Induction of tumoricidal function in CD4+T cells is associated with concomitant memory and terminally differentiated phenotype

(2012) Daniel Hirschhorn-Cymerman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CD8+T Cells: GITR Matters

(2012) Simona Ronchetti et al.   TheScientificWorldJOURNAL

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

(2011) Nicholas S. Wilson et al.   CANCER CELL

Science gone translational: the OX40 agonist story

(2011) Andrew D. Weinberg et al.   IMMUNOLOGICAL REVIEWS

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Inhibitory Fc  Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

(2011) F. Li et al.   SCIENCE

Signaling Through OX40 Enhances Antitumor Immunity

(2010) Shawn M. Jensen et al.   SEMINARS IN ONCOLOGY

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

(2009) Daniel Hirschhorn-Cymerman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fc-mOX40L Fusion Protein Produces Complete Remission and Enhanced Survival in 2 Murine Tumor Models

(2009) Rebecca E. Sadun et al.   JOURNAL OF IMMUNOTHERAPY

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

(2008) Sergio A. Quezada et al.   JOURNAL OF EXPERIMENTAL MEDICINE

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

(2008) Silvia Piconese et al.   JOURNAL OF EXPERIMENTAL MEDICINE